Krystal Biotech (KRYS) Competitors

Inhibrx (NASDAQ:INBX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Does the MarketBeat Community believe in INBX or KRYS?

Krystal Biotech received 247 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 66.83% of users gave Krystal Biotech an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.

Company	Underperform	Outperform
Inhibrx	Outperform Votes 31 60.78%	Underperform Votes 20 39.22%
Krystal Biotech	Outperform Votes 278 66.83%	Underperform Votes 138 33.17%

Which has higher earnings & valuation, INBX or KRYS?

Krystal Biotech has higher revenue and earnings than Inhibrx. Inhibrx is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx	$1.80M	473.06	-$241.36M	-$5.03	-3.23
Krystal Biotech	$50.70M	90.16	$10.93M	$1.87	85.59

Do institutionals and insiders hold more shares of INBX or KRYS?

82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is INBX or KRYS more profitable?

Krystal Biotech has a net margin of 0.00% compared to Krystal Biotech's net margin of -13,408.95%. Inhibrx's return on equity of -5.74% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx	-13,408.95%	-678.51%	-91.73%
Krystal Biotech	N/A	-5.74%	-5.45%

Do analysts recommend INBX or KRYS?

Inhibrx currently has a consensus target price of $27.00, suggesting a potential upside of 66.15%. Krystal Biotech has a consensus target price of $177.63, suggesting a potential upside of 10.98%. Given Krystal Biotech's higher possible upside, equities analysts clearly believe Inhibrx is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Krystal Biotech	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, INBX or KRYS?

Inhibrx has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Does the media prefer INBX or KRYS?

In the previous week, Inhibrx had 2 more articles in the media than Krystal Biotech. MarketBeat recorded 6 mentions for Inhibrx and 4 mentions for Krystal Biotech. Inhibrx's average media sentiment score of 0.98 beat Krystal Biotech's score of 0.78 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Inhibrx on 13 of the 18 factors compared between the two stocks.